title: miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W.
abstract: Increasing evidence has demonstrated that small non-coding microRNAs (miRNAs) play important roles in cancer development and progression. Recent studies have shown that microRNA-335 (miR-335) functions as an oncogene or a tumor suppressor in various human cancer types, but its role in clear cell renal cell carcinoma (ccRCC) remains poorly understood. In our study, we firstly found that the expression level of miR-335 was significantly downregulated in ccRCC tissues versus corresponding non-tumor tissues and the low expression of miR-335 was significantly associated with lymph node metastasis, larger tumor size, and poor T stage. Then, we found that overexpression of miR-335 significantly suppressed the proliferation and invasion of 786-O and CaKi-1 ccRCC cell lines. We subsequently found that miR-335 could interact with the 3'-untranslated regions (3'UTR) of B-cell CLL/lymphoma 2 like 2 (BCL-W or BCL2L2) messenger RNA (mRNA) and repress its expression. In addition, re-expression of BCL-W (without the 3'UTR) could partially abrogate the miR-335-induced 786-O and CaKi-1 ccRCC cell proliferation and invasion inhibition. Furthermore, we found that expression patterns of miR-335 were inversely correlated with those of BCL-W mRNA in ccRCC tissues. Taken together, these results indicate that miR-335 acts as a novel tumor suppressor to regulate ccRCC cell proliferation and invasion through downregulation of BCL-W expression.
authors.affiliation: Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
authors.forename: Kefeng
authors.initials: K
authors.lastname: Wang
authors.affiliation: Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
authors.forename: Xiaonan
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
authors.forename: Yunhong
authors.initials: Y
authors.lastname: Zhan
authors.affiliation: Department of Pathology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
authors.forename: Weiguo
authors.initials: W
authors.lastname: Jiang
authors.affiliation: Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
authors.forename: Xuefeng
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
authors.forename: Xia
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China. wubin1959@163.com.
authors.forename: Bin
authors.initials: B
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis / Q000235:genetics*; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000235:genetics
chemical_list: D051017:Apoptosis Regulatory Proteins; C491073:BCL2L2 protein, human; C556347:MIRN335 microRNA, human; D035683:MicroRNAs
keywords: BCL-W; Clear cell renal cell carcinoma; miR-335
references.citation: Gynecol Oncol. 2010 Dec;119(3):586-93
references.pmid: 20801493
references.citation: Nat Rev Mol Cell Biol. 2010 Apr;11(4):252-63
references.pmid: 20216554
references.citation: N Engl J Med. 2005 Dec 8;353(23):2477-90
references.pmid: 16339096
references.citation: Gynecol Oncol. 2008 Dec;111(3):478-86
references.pmid: 18823650
references.citation: Oncogene. 2012 Mar 15;31(11):1398-407
references.pmid: 21822301
references.citation: Mol Pharmacol. 2012 Mar;81(3):292-8
references.pmid: 22172575
references.citation: J Neurooncol. 2012 Nov;110(2):155-62
references.pmid: 22886530
references.citation: J Cancer Res Ther. 2014 Nov;10 Suppl:C167-77
references.pmid: 25450277
references.citation: PLoS One. 2012;7(7):e40037
references.pmid: 22802949
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Oncotarget. 2012 Jan;3(1):44-57
references.pmid: 22294552
references.citation: Cancer Lett. 2009 May 8;277(1):22-8
references.pmid: 19097687
references.citation: Cell Tissue Res. 2001 Dec;306(3):347-61
references.pmid: 11735035
references.citation: Cell. 2013 Apr 25;153(3):516-9
references.pmid: 23622238
references.citation: Nature. 2008 Jan 10;451(7175):147-52
references.pmid: 18185580
references.citation: Oncogene. 2014 Feb 6;33(6):679-89
references.pmid: 23353819
references.citation: Cancer Res. 2003 Mar 1;63(5):1093-100
references.pmid: 12615727
references.citation: Exp Ther Med. 2012 Mar;3(3):475-480
references.pmid: 22969914
references.citation: Pathol Oncol Res. 2013 Jul;19(3):529-37
references.pmid: 23456549
references.citation: Mol Cancer. 2011 May 19;10:59
references.pmid: 21592405
references.citation: Tumour Biol. 2013 Oct;34(5):3101-9
references.pmid: 23740614
references.citation: Tumour Biol. 2014 Aug;35(8):8309-18
references.pmid: 24859837
references.citation: Tumour Biol. 2015 Apr;36(4):2875-83
references.pmid: 25492484
references.citation: Curr Pharm Des. 2013;19(7):1242-52
references.pmid: 23570052
references.citation: Oncol Rep. 2013 Aug;30(2):701-6
references.pmid: 23708561
references.citation: Tumour Biol. 2012 Feb;33(1):131-40
references.pmid: 22086373
references.citation: Oncogene. 2008 Apr 3;27(15):2128-36
references.pmid: 17968323
references.citation: J Cell Biol. 2007 Apr 23;177(2):277-87
references.pmid: 17452531
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Urol. 2011 Sep;186(3):1077-83
references.pmid: 21784468
references.citation: Genes Dev. 1999 Aug 1;13(15):1899-911
references.pmid: 10444588
references.citation: Med Oncol. 2012 Dec;29(5):3291-7
references.pmid: 22460837